Your institution may have access to this item. Find your institution then sign in to continue.
Title
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
The article discusses a study on long-term patient-reported outcomes from monarchE conducted by Tolaney and colleagues, published in the journal "European Journal of Cancer," revealing that while some adverse events like diarrhea were more prominent in abemaciclib recipients.